Systemic monotherapy with acitretin for erythrodermic psoriasis: results of a retrospective study of 81 patients
Background: Erythrodermic psoriasis (EP) remains challenging to manage because it is rare and has complex complications. Although acitretin is recommended as an appropriate choice for EP, there is a lack of large-scale evidence. Objectives: This study aims to assess the efficacy and safety of acitre...
Gespeichert in:
Veröffentlicht in: | Therapeutic advances in chronic disease 2023-01, Vol.14, p.20406223231178412-20406223231178412 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Erythrodermic psoriasis (EP) remains challenging to manage because it is rare and has complex complications. Although acitretin is recommended as an appropriate choice for EP, there is a lack of large-scale evidence.
Objectives:
This study aims to assess the efficacy and safety of acitretin as systemic monotherapy in EP patients.
Design:
We retrospectively analyzed data from patients with EP who received at least 3 months of acitretin as systemic monotherapy during hospitalization and out-patient follow-up from January 2005 to May 2021 at the Peking Union Medical College Hospital, China.
Methods:
The efficacy was clinically evaluated after 1, 2, 4, and 12 weeks of treatment, which was classified as a good response (>75% of lesions cleared), partial response (50%–75% cleared), moderate response (25–50% cleared), or no response ( |
---|---|
ISSN: | 2040-6223 2040-6231 |
DOI: | 10.1177/20406223231178412 |